Oversubscribed round reflects surging enterprise demand for device management and security in private LTE/5G deployments. 

BOSTON, Oct. 16, 2025 — OneLayer, the leader in private LTE/5G OT management and Zero Trust security, today announced it has closed a $28 million Series A round led by Maor Investments with participation from McRock Capital, Chevron Technology Ventures and existing investors Viola Ventures, Grove Ventures and Koch Disruptive Technologies. 

The Series A round brings total funding to more than $43 million, enabling OneLayer to accelerate its go-to-market motions and expand product capabilities as enterprises rapidly adopt private cellular networks for critical operations. The investment reflects the company’s explosive growth, with 6X growth last year and 3X growth this year backed by a strong customer pipeline extending through 2026. 

“Private 5G represents a massive market opportunity, with enterprise demand far outpacing the industry’s ability to deliver simple, secure solutions,” said Ido Hart, Partner at Maor. “OneLayer solves this by translating cellular networks into enterprise IT language, eliminating the need for specialized cellular expertise. At its core, OneLayer is building the essential infrastructure layer that will make private 5G as ubiquitous as WiFi or any LAN.” 

OneLayer’s mission is to secure and manage all private cellular network devices with enterprise-grade capabilities while eliminating the need for specialized cellular expertise. The company’s platform transforms private cellular environments from operational silos into integrated enterprise networks, providing complete device visibility, security, and control through familiar IT management tools.

The funding round was highly competitive and oversubscribed, reflecting strong investor confidence in OneLayer’s vision and proven momentum. OneLayer has demonstrated significant market traction across multiple verticals, including utilities, manufacturing, mining, airports, and critical infrastructure, with proven deployments spanning across North America, Europe and Latin America. This includes major expansions at leading fortune 100 manufacturers, with enterprises scaling from initial deployments to comprehensive multi-site deployments spanning numerous facilities. 

“Enterprises are deploying private cellular networks at unprecedented scale, but they’re struggling with device visibility, security gaps, and operational complexity that didn’t exist with traditional IT infrastructure,” said Dave Mor, CEO and Co-Founder of OneLayer. “The demand for solutions that bridge this gap is explosive, customers need to manage thousands of cellular-connected devices with the same confidence and control they have over their existing IT assets.” 

“OneLayer enables secure private 5G for industrial automation and autonomy – the foundation Industrial AI needs to scale,” said Scott MacDonald, Co-founder & Managing Partner of McRock Capital. “Private cellular networks represent the next wave of digital transformation, but connectivity without security is a house of cards. OneLayer provides the missing layer of trust that enterprises need to adopt private 5G with confidence.” 

“OneLayer’s software platform holds promise to improve private cellular network reliability and integration for industrial companies, offering better visibility, cost efficiency and security,” said Jim Gable, Vice President of Innovation within Chevron’s Technology, Projects and Execution division and President of Technology Ventures at Chevron. “This is the latest investment from our Core Venture Fund, which focuses on high-growth startups and breakthrough technologies that have the potential to improve Chevron’s core businesses, as well as create new opportunities for growth. We welcome OneLayer to the portfolio.”

OneLayer’s platform has proven essential for organizations deploying private LTE and 5G networks at scale. Notable deployments include: 

• Southern Linc’s regional LTE network spanning 122,000 square miles across Alabama, Georgia, and southeastern Mississippi, supporting diverse devices from grid control systems to mission-critical push-to-talk services.

• Evergy’s private LTE network, built to eventually cover their 1.7 million customers in Kansas and Missouri; currently supporting thousands of devices, including Internet of Things (IoT) sensors, smart meters, OT and other cellular devices. 

• Latin America mining operations where OneLayer enabled automated processes, improved operational efficiency, and secure deployment of new production sites through comprehensive device discovery, classification, and network segmentation.

OneLayer’s comprehensive partner ecosystem spans the entire private cellular value chain, from cellular leaders Nokia and Ericsson to leading cellular router manufacturers Digi, Cradlepoint, and Multitech; CMDBs ServiceNow and SolarWinds; channel partners and integrators World Wide Technology (WWT), Burns & McDonnell (B&M), Anterix, and Future Technologies; and leading cybersecurity vendors such as Palo Alto Networks, Fortinet, Checkpoint, Claroty, and more.   

Adding to the strong revenues from its expanding customer base, the company will use the Series A funding to: 

• Accelerate go-to-market initiatives in response to surging enterprise demand 

• Expand product capabilities to provide customers a platform that solves their critical operational pains 

• Scale geographic expansion beyond North America following successful entry into Latin American markets, and further expand European operations 

OneLayer’s growth reflects the broader market transformation as private cellular networks evolve from carrier-grade infrastructure to enterprise-managed networks. With partnerships across major 5G vendors and proven success in critical verticals and leading enterprises, OneLayer has become the defacto solution for managing and securing the rapidly expanding private cellular market. 

About OneLayer 
OneLayer provides advanced asset management, operational intelligence, and Zero Trust security for private LTE and 5G networks. Its technology empowers enterprises to manage their cellular networks seamlessly without the need for cellular expertise. For more information, visit www.onelayer.com. 

Stay Current:
Subscribe to OneLayer’s Investor Newsletter

Media Contact: 
Mor Ben-Horin 
[email protected]

Photo: https://mma.prnewswire.com/media/2798108/OneLayer_Co_Founders.jpg
Logo: https://mma.prnewswire.com/media/2455348/OneLayer_Logo.jpg

SOURCE OneLayer

• With $1 billion in insured value, Stand brings mitigation-first coverage to the largest catastrophe market in the U.S.

SAN FRANCISCO, Oct. 16, 2025 — Stand, the company reimagining insurance for catastrophe-exposed properties, today announced the close of its $35 million Series B funding round. The round was led by Eclipse, alongside previous investors Inspired Capital, Lowercarbon Capital, and Equal Ventures. Since its launch just over a year ago, Stand has grown rapidly, underwriting $1 billion in insured value in its first market, wildfire-exposed California.

The new funding will support Stand’s expansion into Florida, one of the largest and most volatile catastrophe markets in the United States. According to NOAA, the state has experienced 94 separate billion-dollar disasters since 1980, with the last seven events alone resulting in more than $1 trillion in losses. Citizens Property Insurance Corporation, Florida’s state-run insurer of last resort, currently holds nearly $300 billion in exposure, underscoring both the scale of the market and the urgent need for sustainable private capacity.

“Insurance should play a central role in creating resilient communities,” says Dan Preston, co-founder and CEO of Stand. “The scale of risk in Florida demands a new model: One that links coverage to hardening homes against wind storms. That’s what Stand is building. By expanding into the largest catastrophe market in the country, we’re working hard to make this a reality for the world’s property owners.”

Stand’s approach to insurance is rooted in resilience. By linking coverage to mitigation upgrades, such as hardening homes against wind, fire, and flood, Stand helps homeowners reduce their risk while lowering costs over time. Stand’s underwriting is informed by physics-based models, first applied to wildfire and now extended to wind, offering a more precise view and clear assessment of how structures withstand extreme weather events.

Damage due to weather-related catastrophes have topped $146 billion per year on average in the US over the last decade, while access to insurance coverage has diminished. Insurers are departing states worst-hit by disasters and hundreds of thousands of homeowners have been left without coverage after large insurers either cancelled policies or denied renewals.

“Over the last 10 years, U.S. weather disasters have caused over $1.4 trillion in losses — with less than half insured,” said Aidan Madigan-Curtis, Eclipse partner and board director at Stand. “Rising costs and shrinking coverage are leaving American families exposed. Eclipse’s $30M investment in Stand reflects our conviction that resilience is the future, giving property owners the tools to safeguard their properties and their futures.”

Led by industry veterans with decades of experience across insurance, technology, and applied science, and backed by top investors and reinsurers, Stand is recognized for outstanding claims management and customer service. With operations now spanning California and Florida, Stand is scaling its mission to protect homes in the world’s most catastrophe-prone regions.

Please visit standinsurance.com for additional details.

For inquiries, please email: [email protected]

SOURCE Stand Insurance

Second Nature’s next generation AI-based training solution is set to build on existing success with major brands such as Oracle, Zoom, Adobe, Teleperformance and Check Point

NEW YORK, Oct. 16, 2025 — Second Nature, the sales and service AI roleplay platform, has announced today a Series B funding round of $22m, led by Sienna VC and supported by Bright Pixel, StageOne Ventures, Cardumen, Signals VC, and Zoom, which is also a customer. Building on notable industry recognition such as selection by Open AI during its beta stage, the company co-founded by a former Facebook lead engineer and a Kaltura senior executive will use the funding to expand its operations and further refine its industry-leading AI sales training technology.

Second Nature creates a data model of each company’s sales and service playbook by analyzing recorded calls, marketing collateral, scripts, and other customer-facing materials. From this, it generates a library of AI-driven roleplays that mirror the most common scenarios teams encounter. These roleplays enable realistic practice with AI-powered avatars that can simulate objections, challenges, and diverse customer responses. After each conversation, the system provides targeted feedback against customizable performance metrics. Highly scalable and quick to deploy, customers can build their first AI roleplays within an hour of onboarding, with support for more than 20 languages, multiple scenarios, and a range of conversational moods.

With businesses incorporating AI into more functions than ever before, sales is one area doubling down on AI to find that edge. McKinsey highlighted that companies which invest in AI enjoy a revenue uplift of up to 15% and a sales ROI increase of up to 20%, underscoring the huge potential for high-impact, AI-driven tools in this arena. Through its interactive, sophisticated AI-powered roleplaying simulation, Second Nature has consistently demonstrated how it is transforming sales and service performance, meeting and surpassing industry expectations.

Across its portfolio of major brands and household names including the likes of Zoom, Oracle, Adobe, Teleperformance and Check Point among others, sales increased by over 20% following an average of only 30 minutes practicing per trainee with Second Nature. Likewise, onboarding time decreased substantially – in some cases shaving three weeks off a typical nine week process.

Ariel Hitron, Co-Founder and CEO at Second Nature said, “The introduction of AI is rapidly changing the playbook for sales, service, customer-facing, and go-to-market teams. From Fortune 100 enterprises to fast-growing startups, companies use Second Nature to help their teams adapt to this new reality, onboarding faster, improving performance, and rolling out new product messages more effectively. As a leader in this space, this new funding enables us to accelerate and expand our product and technology innovation, seamlessly integrating personalized AI training, coaching, and certification into the workflow of any team.”

Second Nature has been deployed across a range of industries, from HR to education, healthcare to waste management, and is applicable to any customer facing setting. Its success has already been demonstrated with customers such as insurance marketplace GoHealth, with reported onboarding time being down by 33%, as sales increased by more than 20%. While video conferencing leader Zoom saw opportunities increase from 2.78 per month to over 6, while experiencing a 100% sales employee participation rate.

“Second Nature is setting the standard for AI roleplay training. Their platform helps sales teams practice, improve, and perform faster and at scale. This foundation puts them in a strong position to execute on a long-term vision: delivering the next generation of AI Sales Agents, the next big pillar in modern go-to-market strategy. We are proud to back Ariel, Alon, and their team, for the precision, impact, and long-term value they bring,” said Mikaël Pereira, Partner at Sienna VC

“Second Nature is an innovator, pioneering the AI role-play market. In 2019 we made our initial investment, and since then have seen how Second Nature is continuously transforming AI role-play technology into real, quantifiable business impacts for leading global enterprises. Our continued support highlights our confidence in the growing market and in Second Nature’s ability to maintain and expand its leadership,” commented Tal Slobodkin, Managing Partner at StageOne Ventures

Gonzalo Martinez de Azagra, Founder and General Partner at Cardumen Capital added: “Second Nature is the gold standard in Sales training and Certification. As such they have an unmatched sales call dataset that can also help them dominate AI driven sales calls in the future.”

“When you see a customer increase from a $50k pilot to a $500k contract that then gets increased to over $1m per year, you know that the software does have full product market fit with enterprises. We are delighted investors in Second Nature,” commented Jens Lapinski, Founder and Managing Partner, Angel Invest.

About Second Nature

Second Nature is an AI-powered dynamic training platform, which provides a virtual partner to practice customer exchanges, sales pitches and other realistic scenarios. Its conversational AI engages in discussions with sales and customer service reps, scoring them, and helping them improve on their own so that they can ace every conversation  Second Nature was founded in 2019 by Ariel Hitron, a seasoned tech entrepreneur who helped scale Kaltura from startup to global success and Alon Shalita, a former lead engineer at Facebook.

About Sienna VC

Sienna VC is a Paris-based venture capital firm investing in early growth tech companies. With over ten years of active investments in Israel, its team is the most active European investor in the Israeli ecosystem. Sienna acts as a bridge to Europe, helping founders expand and scale across the continent through its deep local networks and operational support.

About StageOne Ventures

StageOne Ventures is a seasoned venture capital firm with over 25 years of experience leading seed-stage investments and helping visionary founders build disruptive, high-impact companies. StageOne has a proven track record of turning early innovation into market leaders. Investing out of our 4th $150M fund, we support over 29 active portfolio companies, focusing on Israeli founders globally, leading seed rounds with continued support through Series B, and investing in enterprise technologies spanning cybersecurity, SaaS, AI, DevOps, and Deeptech. Beyond capital, we provide hands-on partnership through business development, strategic introductions, and access to strong founder and executive communities, all designed to help our companies scale and succeed.

About Bright Pixel

Bright Pixel Capital is the technology investment arm of the multinational group Sonae. With special focus on cybersecurity, infrastructure software, retail technologies, business applications and emerging tech, it has a portfolio of more than 60 companies, from early to growth stages. Bright Pixel acts as a partner that brings specialized know-how, global footprint, and a wealth of experience in helping companies from early stage to IPO. For more information, visit brpx.com.

About Cardumen Capital

Cardumen Capital is a global venture capital firm and asset management company with presence in Europe, Middle East and Asia that invests in world-class founders who bring the future into the present.

With €300M in Assets Under Management, Cardumen Capital’s extensive portfolio encompasses tech companies and fund investments across three different strategies, with global coverage.

Cardumen Capital strives to be the most active investor for both entrepreneurs. Its portfolio benefits from decades of experience in the world’s most important tech ecosystems, a culture of radical collaboration, and absolute availability. Cardumen Capital is backed by world-leading institutional investors and corporations.

Media Contact

Gavin Horwich, Headline Media
[email protected]

Photo – https://mma.prnewswire.com/media/2797080/Second_Nature.jpg

SOURCE Second Nature

SEATTLE, Oct. 16, 2025 — Brook.ai is making remote care an integral part of U.S. healthcare, extending continuity of care outside the traditional practice setting and delivering measurable improvements in patient outcomes. The company’s success has prompted new investment led by UMass Memorial Health and Morningside, accelerating Brook’s national expansion through a $28 million Series B to further its equitable, accessible care model.

“At UMass Memorial, we’ve seen firsthand how Brook’s remote care model improves patient outcomes and supports population health. That’s why we’re proud to lead this investment and expand our use of the platform, helping scale a solution that delivers continuous care at a critical moment for health systems,” said Eric Dickson, MD, President and CEO, UMass Memorial Health. “Our goal is to back models that expand access, improve equity, and strengthen the sustainability of care for our patients and community.”

Brook has achieved positive health outcomes with its partners, including reducing congestive heart failure (CHF) readmissions by 90% and achieving an 80% increase in controlled populations with hypertension in as little as six weeks.

This investment in Brook comes at a pivotal time as the company experiences significant growth. Always-on, personalized care with Brook’s platform has driven increased patient satisfaction and strong patient engagement— reflected in an 82% retention rate and Net Promoter Score of 66, placing Brook in the “excellent” category — and has fueled 204% patient growth over the past year, underscoring its growing value to patients and providers nationwide.

“Outcomes-focused support makes a real difference for patients and providers, and what really sets Brook apart is that people actually use our platform at home, every day. That engagement drives better outcomes and growth, as shown by the ongoing expansion we see with our customers and investors,” said Oren Nissim, CEO, Brook.ai. “Our partnership with UMass Memorial and Morningside in our latest investment round allows us to expand our outcomes-driven model to more health systems at a moment when it’s needed most.”

“Brook’s ability to deliver robust clinical outcomes while also creating clear benefits to its health system partners has created a truly differentiated platform, and we are proud to be co-leading with UMass Memorial on this investment,” said Stephen Bruso of Morningside. “This round will enable Brook to continue scaling its commercial activities while also expanding its clinical reach to become even more impactful to our partners.”

Brook’s remote care solution comes at a critical time for healthcare providers, as reimbursement models and care-at-home adoption accelerate toward 2026. It addresses urgent system-wide challenges, including workforce shortages, rising chronic disease, and mounting costs — by delivering outcomes-driven remote care that health systems can implement quickly.

“Our solution addresses the key barriers to adoption, allowing providers to implement remote care without the burden of building infrastructure, hiring staff, or managing complex billing processes,” added Nissim.

Brook’s platform is designed for easy adoption — health systems can be up and running in 30 days, with no capital expenditure required.

The Series B funding will be used to:

• Expand services for additional patient populations and conditions
• Increase product and engineering headcount, with a focus on safe AI development
• Product enhancements to support higher engagement and better outcomes
• Expand operations to support growth

For more information about Brook’s remote care platform, visit brook.ai.

About Brook

Brook.ai is enabling the future of remote patient care with a unique offering that blends remote clinical teams with AI to deliver continuous, always-on care. Brook augments traditional healthcare by combining intelligent data collection and analysis with compassionate support from skilled health specialists — shifting the paradigm from reactive, intermittent check-ups to proactive, ever-present, habitual care. For patients, this means getting better, faster, with instant access to care teams from the comfort of home. Providers can extend their care into patients’ homes without increasing clinician workloads. And payers can help members improve long-term health, slow disease progression, and reduce costly admissions. Brook’s personal health assistant, a part-AI, part-nurse system, is trained on millions of patient conversations over the past six years — providing timely nudges, insights, and recommendations. It all translates into better patient outcomes and ROI. Learn more at brook.ai.

Media contact:

Katlyn Nesvold, Amendola for Brook

[email protected]

SOURCE Brook.ai

CINCINNATI and SEATTLE, Oct. 16, 2025 — SaaS Capital, the leading provider of growth debt for recurring-revenue software businesses, today announced the closing of SaaS Capital Fund V, LP, totaling $100 million. The new fund enables SaaS Capital to expand its support for “Subscription AI and Software” (SaaS) businesses with non-dilutive, flexible capital.

“Founder-friendly, flexible growth debt has helped hundreds of recurring-revenue companies scale efficiently while preserving control,” said Rob Belcher, Managing Director at SaaS Capital. “With Fund V, we can now support an important next wave: subscription AI application companies building durable, recurring revenue technology businesses alongside traditional SaaS. Our goal is to provide committed, right-sized facilities that adapt to growth, reduce financing friction, and lower the overall cost of capital.”

Fund V will continue SaaS Capital’s strategy of providing committed, multi-year growth debt facilities to companies with meaningful recurring revenue, enabling investments in sales and marketing, product development, acquisitions, and working capital. The firm will maintain its focus on business-to-business (B2B) companies with at least $3 million in annualized recurring subscription revenue, whether they are bootstrapped independents or backed by equity investors.

“SaaS Capital has always focused on pragmatic, data-driven credit for recurring-revenue companies,” said Randall Lucas, Managing Director at SaaS Capital. “Fund V extends that approach to serve the growing number of teams productizing AI into subscription applications, while we continue to back the core SaaS market. The through-line is the same: align with founders on efficient growth, protect optionality, and deliver capital that works with, not against, the operating plan.”

For more information, visit www.saas-capital.com.

About SaaS Capital

SaaS Capital is the leading provider of growth debt designed explicitly for B2B SaaS and subscription AI application companies. SaaS Capital’s growth debt is structured to provide a significant source of committed funding, deployment flexibility, and lower overall cost of capital, all while avoiding the loss of control associated with selling equity. SaaS Capital was the first to offer lending alternatives to SaaS businesses based on their future recurring revenue. Since 2007, SaaS Capital has committed more than $375 million in growth debt facilities to deliver better outcomes for more than 120 clients, resulting in more than $2 billion in total enterprise value created. Visit www.saas-capital.com to learn more.

SaaS Capital lends $2M to $15M to B2B Subscription AI and Software (SaaS) companies with $3M in ARR and up, registered and banked in the U.S., Canada, Ireland, or the U.K. Companies do not need to be venture-backed, nor do they need to be profitable. The borrowing base formula is typically 5x to 8x monthly subscription revenue.

Contact
Rob Belcher
[email protected]
303-870-9529

SOURCE SaaS Capital

Series G round led by Neuberger Berman Funds

SAN FRANCISCO, Oct. 16, 2025 — Upgrade, Inc., a fintech company that offers affordable and responsible credit and banking products to mainstream consumers, today announced that it raised $165 million in new equity investment. Upgrade’s Series G Preferred Round was led by Neuberger*, with participation from LuminArx Capital Management**. Existing shareholders, including DST Global, Ribbit Capital and several others, also increased their investment in the company. Peter Sterling, Head of Specialty Finance at Neuberger, is joining Upgrade’s Board of Directors.

Upgrade has delivered over $42 billion in affordable credit to over 7.5 million customers since its inception in 2017. It offers a wide range of banking and credit products, including mobile banking, BNPL, credit cards, personal loans, home improvement financing and auto financing. Upgrade has established unique distribution channels with hundreds of airlines, cruise lines and other travel brands, as well as thousands of home improvement contractors and car dealerships across the country.

“Upgrade presents an unmatched opportunity in fintech,” said Peter Sterling. “As many companies in the space struggle with acquisition costs and monetization strategy, Upgrade has sustained profitable growth through a multi-product, multi-channel strategy that relies on low-cost, proprietary distribution channels to acquire new customers and its ability to monetize users through multiple products. We have known Renaud and the Upgrade founding team for over a decade and are very excited to expand our partnership.”

Upgrade recently achieved significant growth milestones, including $2 billion dollars in cumulative home improvement financing and $1 billion in auto financing, denoting fast growth as both products launched in the last three and two years, respectively.

“We are thrilled to expand our relationship with Neuberger and welcome Peter as a new board member,” said Upgrade co-founder and CEO Renaud Laplanche. “We are planning to use the new equity capital to keep developing new products and expand distribution to achieve our goal of helping more mainstream consumers get the banking and credit products they need today, while improving their financial and credit standing in the long run.”

Upgrade, Inc. has raised $750 million in equity capital since inception. BofA Securities served as the exclusive placement agent to Upgrade.

About Upgrade 

Upgrade is a financial technology company that offers affordable and responsible credit, mobile banking, and payment products to mainstream consumers. Since its inception in 2017, Upgrade has delivered over $42 billion in credit to over 7.5 million customers. Upgrade’s platform includes six core products: Personal Loans, Credit Cards, Mobile Banking, BNPL, Home Improvement Financing and Auto Financing. Loans and credit lines are issued, and banking services are provided, by Cross River Bank, a New Jersey State Chartered Commercial Bank, Member FDIC, Equal Housing Lender, Blue Ridge Bank, a nationally chartered commercial bank, Member FDIC, and Celtic Bank, a Utah State Chartered Industrial Bank, Member FDIC.

Upgrade is headquartered in San Francisco, California, with an operations center in Phoenix, Arizona, a technology center in Montreal, Canada, and regional offices in Atlanta, Georgia, and Irvine, California.

Follow Us on Social Media:

SOURCE Upgrade, Inc.

Zaloganan (PLG0206) enters Phase 2/3 study for treating prosthetic joint infections (PJI)

PITTSBURGH, Oct. 16, 2025 — Peptilogics, a clinical-stage biotechnology company developing transformative surgical therapeutics to effectively treat and prevent serious medical device infections, today announced the completion of an oversubscribed $78 million Series B2 financing round. The funding will support the company’s Phase 2/3 pivotal trial of zaloganan (PLG0206), an investigational treatment for prosthetic joint infections (PJI).

Presight Capital, Thiel Bio, and Founders Fund led the round, with participation from new investors AMR Action Fund, Narya Capital, and Beyond Ventures. This brings Peptilogics’ total equity funding to approximately $120 million, along with substantial grant support from CARB-X.

“What these investors understood is that hardware-related infections like PJI are different from other common infections. We chose to focus on this huge unmet need because the lack of effective therapeutic options alters the commercial landscape that has made antibiotic development difficult,” said Peptilogics’ CEO Jonathan Steckbeck, PhD. “Developing treatments for these infections allows us to create a new category of surgical therapeutics for patients who currently have to undergo multiple life-changing surgeries to eliminate the infection.”

Addressing Orthopedic Surgery’s Most Challenging Complication to Create a New Category of Surgical Therapeutics

Prosthetic joint infections are a devastating complication that can turn a successful joint replacement into a patient’s worst nightmare. With 45,000 PJI cases each year in the U.S. and no approved therapeutics specifically indicated for this condition, patients face limited and often unsuccessful treatment options.

Current approaches force difficult choices: implant-preserving procedures such as DAIR (debridement, antibiotics, and implant retention) have reported failure rates of approximately 50% in published literature, while grueling two-stage revision procedures require multiple surgeries, extended hospitalization, and months of disability, yet still fail 15-25% of the time. The financial burden is equally staggering, with total PJI costs often reaching more than $390,000 per patient, according to a study by Hany Bedair, MD published in Clinical Orthopedics and Related Research.

“Biofilm is the common enemy and the reason why existing standard-of-care surgical interventions fail, even with systemic antibiotics,” says Nick Pachuda, a former orthopedic surgeon and Peptilogics Chief Operating Officer. “Hardware-related infections are difficult to treat because bacteria on foreign surfaces hide in drug-resistant biofilm that current antibiotics cannot eliminate. Zaloganan quickly penetrates the biofilm locally and kills the hiding bacteria.”

In Peptilogics’ Phase 1b study, zaloganan irrigation administered during DAIR procedures resulted in 13 of 14 patients (93%) remaining infection-free at 12 months. These encouraging results supported the company’s decision to advance into pivotal trials.

Growing Problem, Expanding Opportunity

The challenge is growing as more joint replacement surgeries are expected. Projections show that by 2030, 3.48 million knee and 572,000 hip replacements will be done each year in the U.S., each with a PJI risk that current medicine cannot fully manage.

The implications reach well beyond individual patients. Healthcare systems are under increasing pressure as PJI cases strain resources through longer hospital stays, repeat surgeries, and complex care coordination. For investors, this represents a substantial and growing market opportunity where effective treatment could deliver significant value to patients, providers, and payers alike.

Regulatory and Development Progress

Peptilogics has received multiple regulatory designations that support the development pathway for zaloganan, including:

• QIDP (Qualified Infectious Disease Product) designation, which provides 5 additional years of market exclusivity upon approval
• Orphan Drug Designation for the treatment of PJI
• Fast Track Designation to facilitate development and expedite FDA review

The upcoming Phase 2/3 randomized, placebo-controlled superiority trial will enroll 240 patients beginning in December 2025, with the primary endpoint measuring the reduction in clinical failure rates. The study will also evaluate health economics measures including hospitalization duration, readmission rates, and additional surgical procedures to quantify the cost savings that zaloganan can create for hospitals, health systems, and payers.

“Periprosthetic joint infections are a striking example of how antimicrobial resistance is rapidly undermining modern medicine,” said AMR Action Fund CEO Henry Skinner, PhD. “The financial costs, diminished quality of life, and mortality associated with such infections are frankly unacceptable, and we are pleased to support the Peptilogics team as they advance zaloganan through the clinic and toward patients in need.”

About Peptilogics

Peptilogics is developing therapeutics for orthopedic hardware-related infections. The company’s lead candidate, zaloganan (PLG0206), is an investigational treatment for prosthetic joint infections currently in clinical development. For more information, visit www.peptilogics.com.

About the Investor Syndicate

The investor syndicate is a group of leading venture firms and strategic healthcare investors who share a commitment to advancing transformative technologies. These investors have backed paradigm-shifting companies including AbCellera (ABCL), Atai Life Sciences (ATAI), New Amsterdam Pharma (NAMS), Compass Pathways (CMPS), Kriya Therapeutics, and F2G. This group combines deep domain expertise with a shared commitment to advancing breakthroughs that improve patient outcomes and redefine standards of care — creating an alignment of capital, science, and purpose to accelerate meaningful change for the healthcare system.

Media Contact:
Kate Kaminsky
[email protected]
1-475-213-3198

SOURCE Peptilogics

STOCKHOLM, Oct. 16, 2025 —

Delivering on our priorities

“It has been a busy third quarter across public and private markets, with activity picking up in Asia, Europe and the US. As clients increasingly seek diversification across geographies and asset classes, EQT’s global platform is well positioned to deliver. In Q3, we maintained our focus on investment and exit activity around the world, made significant headway in our fundraising efforts, and continued to scale our evergreen offerings. This reflects the priorities set earlier in the year: striving for excellence in dealmaking and value creation across everything we do and continuing to build the most attractive counterparty for clients in the private markets industry.”

Per Franzén,
CEO and Managing Partner

Highlights for the period Jul-Sep 2025 (Jul-Sep 2024)

Strategic

• EQT maintained its focus on realizations and distributions to clients during the third quarter, paced by public market exits
• Fundraising continued with healthy momentum for EQT’s strategies across the globe, notably BPEA IX (Asia), EQT XI (Europe and North America), and certain other funds
• During the quarter, EQT introduced an ELTIF evergreen structure that broadens access to EQT Nexus PE for individual investors across Europe, enabling strategic distribution partnerships in key growth markets
• Fundraising continued for EQT’s recently launched US evergreen vehicle focused on private equity, as well as for EQT’s Nexus strategies in Europe and Asia, while preparations for a US evergreen vehicle focused on infrastructure continued
• EQT continued work to identify operational efficiencies across the platform to ensure it is set for continued scalable growth

Fundraising

• Gross inflows amounted to €2bn (€3bn), primarily driven by closed out commitments from BPEA IX and selected other funds
• FAUM increased to €139bn (€134bn) and Total AUM was €267bn (€246bn)
• As of 16 October 2025, BPEA Private Equity Fund IX has received commitments of $12.0bn, with closed and pending commitments exceeding its $12.5bn target fund size. Fundraising is expected to materially conclude before year-end, and the fund is expected to reach its $14.5bn hard cap upon final close in early 2026
• Following the launch of EQT XI in June 2025, fundraising is progressing well, underpinned by strong exit activity within Private Capital Europe & North America. EQT XI has a target fund size of €23bn and is expected to be activated during the first half of 2026. EQT XI will not contribute to gross inflows or FAUM until activation
• Fundraising continued for EQT Healthcare Growth, EQT Transition Infrastructure and EQT Exeter Logistics Europe V. All funds charge fees on committed capital from the date of activation¹
• EQT launched an open-ended Active Core Infrastructure fund. The fund is a continuation of our successful Active Core Infrastructure (ACI) strategy, which was initiated with the ACI I fund. The open-ended fund will target long-term, yield-oriented opportunities in energy, digital, and transport infrastructure across OECD countries, leveraging EQT’s active ownership approach and industrial mindset

Investment performance

• All Key funds continue to perform On or Above plan.
• Key fund valuations increased by 3% on average, during the period. Performance in EQT Infrastructure funds was particularly strong, supported by strong operational performance and supportive valuation feedback for companies being readied for exit

Investment activity

• Total investments by the EQT funds amounted to €‌5‌bn during the period, which was approximately €‌2bn higher than in Q2. EQT Private Capital was particularly active, announcing new investments across Europe, Asia and North America within focus themes such as health and well-being and the digitalization of society
• In addition, EQT provided co-investment opportunities of €2bn for its clients during the period

Exit activity

• Total gross fund exits amounted to €‌2‌bn during the period, as EQT continued to seize supportive market conditions to execute various realizations
• As of September, EQT has been the most active private markets firm globally in terms of Equity Capital Markets activity this year². In Q3, additional sell-downs were made in Galderma and Waystar (EQT Vlll), Beijer Ref (EQT IX), Kodiak Gas Services (EQT Infrastructure Ill, EQT Infrastructure IV) and Horizon Robotics (BPEA VII)
• During the past twelve months, gross exits by the EQT funds amount to €‌19bn. In addition, €6bn of proceeds were generated on behalf of clients from realizations of co-investments

People

• The number of full-time equivalent employees (FTE) was ‌1,941‌ (‌‌1,861‌) at the end of the period, a net increase of 33 FTEs during the quarter. Hires were primarily made within the Infrastructure and Capital Raising teams to support EQT’s growth agenda
• In line with EQT’s ongoing work to create an even more streamlined and high-performing organization, operational efficiency actions are being implemented during the third and fourth quarter. By year-end, EQT expects the number of FTEs to return towards the number of FTEs at the start of 2025

Other

• EQT completed a share buyback program of 5.5 million ordinary shares (€171 million). As previously communicated, EQT expects to execute share buyback programs twice a year to offset the dilution impact from EQT’s equity incentive programs. Over the last twelve months, EQT has executed share buybacks of €298 million and distributed €416 million in dividends
• Lock-ups related to 11% of EQT’s share capital expired during the quarter, with approximately 35% of released shares being owned by current members of the Board or Executive Committee. Since the IPO in 2019, EQT’s free float has increased from approximately 24% to almost 50%
• At the end of the period, the number of portfolio companies with validated science-based targets amounted to 65, representing more than 70% of invested capital. In addition, four companies are in the process of setting targets

Events after the reporting period

• EQT’s Nomination Committee has proposed Jean Eric Salata, Chair of EQT Asia and founder of Baring Private Equity Asia, as the next Chairperson of the EQT Board. He is proposed to succeed EQT’s founder and current Chairperson, Conni Jonsson, at the Annual Shareholders’ Meeting on 12 May 2026
• Investment levels in EQT Key funds as of 16 October 2025 were 60-65% in EQT X, 50-55% in EQT Infrastructure VI and 5-10% in BPEA IX

1. EQT Exeter Logistics Europe V is expected to be activated in Q4 2025
2. Source: Dealogic as of 30 September 2025. Includes all sponsor-related deals YTD, measured in terms of transaction volume

Presentation of EQT AB’s Q3 Announcement 2025

Financial analysts and media are invited to participate in a conference call, including a presentation at 08.30 CEST.

The presentation and a link to follow the webcast and conference call live can be found here and a recording will be available afterwards.

To participate by phone, please register here. You will then receive your personal dial-in details, to be able to ask questions during the Q&A.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected] 
Rickard Buch, Head of Corporate Affairs, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This is information that EQT AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07.00 CEST on 16 October 2025.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-ab–publ–q3-announcement-2025,c4251038

The following files are available for download:

SOURCE EQT

SAN FRANCISCO, Oct. 15, 2025 — California based Graph AI, focused on patient safety and pharmacovigilance, announced its $3 million Seed round, led by Bessemer Venture Partners. The investment will enable Graph to accelerate product innovation, expand its engineering team, and drive global market adoption.

Graph is a prime example of the new wave of AI-native challengers reshaping the pharma and life sciences landscape, especially the $8 billion pharmacovigilance market. Pharmacovigilance, mandated by global drug regulatory authorities, requires pharmaceutical companies to continuously monitor, detect, and report adverse drug events (ADE) across a drug’s entire lifecycle.

Currently, pharma companies outsource this process to services firms, who deploy armies of individuals to manually scrape data from various sources and report ADEs. By keeping a human-in-the-loop only for select regulatory-mandated steps, Graph enables companies to transition from manual, error-prone, and time-intensive workflows to highly automated, AI-driven systems that enhance the efficiency and accuracy of medical reviews while ensuring regulatory compliance.

Founded in 2024, Graph is led by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO), industry veterans with significant experience across leading global organizations including Infosys, Google, and ServiceNow.

In just over a year, Graph AI has delivered remarkable traction with enterprise customers and built a rapidly growing pipeline spanning over 7,000 drugs. Customers have reported up to 70% efficiency gains, 90% faster regulatory reporting, and substantial cost savings while ensuring end-to-end traceability and audit readiness.

The founders said: “The life sciences industry continues to grapple with outdated technology, fragmented point solutions, data silos, and manual handoffs that hinder decision-making and elevate compliance risks. At Graph, we’re addressing these challenges with a unified, AI-native safety platform that integrates context, compliance, and intelligence into a single seamless ecosystem. Our vision is to make patient safety smarter, faster, and more connected, empowering pharmaceutical enterprises to achieve safer outcomes, stronger regulatory confidence, and exponential efficiency across safety operations.“

Nithin Kaimal, Partner at Bessemer Venture PartnersIndia, said: “We’re excited to partner with Graph AI as they redefine labour intensive and inefficient pharmacovigilance workflows through AI-native solutions that prioritize accuracy and scalability. At Bessemer, we’re deeply optimistic about the transformative potential of AI to reimagine traditional services models as for the first time, delivery is shifting from labour arbitrage to intelligence arbitrage, empowering enterprises to work with firms that deliver faster, smarter, and more adaptive solutions. We look forward to supporting the Graph team as they continue to scale new heights.”

Photo: https://mma.prnewswire.com/media/2797185/Raghav_Parvataraju_Graph_AI.jpg

SOURCE Graph AI